Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C4AY
|
|||
| Drug Name |
REGN 3051
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] | Discontinued in Phase 1 | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | MERS-CoV spike glycoprotein (S) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03301090) A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051. U.S. National Institutes of Health. | |||
| REF 2 | Pre- And Postexposure Efficacy of Fully Human Antibodies Against Spike Protein in a Novel Humanized Mouse Model of MERS-CoV Infection. Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43. doi: 10.1073/pnas.1510830112. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.